No products in the cart.
Pre-made Bentracimab benchmark antibody ( Whole mAb, anti-AR-C124910XX therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-059
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Bentracimab biosimilar, Whole Mab: Anti-AR-C124910XX therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti-blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others).[2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor.[3] It is not commercially available.
| Products Name (INN Index) | Pre-Made Bentracimab biosimilar, Whole Mab: Anti-AR-C124910XX therapeutic antibody |
|---|---|
| INN Name | Bentracimab |
| Target | AR-C124910XX |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | 5alb:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | 5alc:HL |
| Year Proposed | 2020 |
| Year Recommended | 2021 |
| Companies | MedImmune,AstraZeneca,PhaseBio |
| Conditions Approved | NA |
| Conditions Active | Haemorrhage (reversal of effects of ticagrelor) |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | AR-C124910XX |
| Package |
Previous slide
Next slide
